ENLV

Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)

About Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Details

Daily high

$1.29

Daily low

$1.12

Price at open

$1.14

52 Week High

$4.59

52 Week Low

$0.81

Market cap

26.8M

Dividend yield

0.00%

Volume

236,814

Avg. volume

259,073

P/E ratio

-1.23

Enlivex Therapeutics Ltd. Ordinary Shares News